Hepion Pharmaceuticals, Inc. (CTRVP) — SEC Filings
Hepion Pharmaceuticals, Inc. (CTRVP) — 42 SEC filings. Latest: 10-Q (Nov 12, 2025). Includes 22 8-K, 6 10-Q, 2 DEF 14A.
View Hepion Pharmaceuticals, Inc. on SEC EDGAR
Overview
Hepion Pharmaceuticals, Inc. (CTRVP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Hepion Pharmaceuticals, Inc. (CTRVP) reported a net loss of $7,620,965 for the nine months ended September 30, 2025, a significant improvement from the $11,644,966 net loss in the same period of 2024. This reduction was primarily driven by a substantial decrease in research and development expenses,
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 8 bearish, 34 neutral. The dominant filing sentiment for Hepion Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Hepion Pharmaceuticals, Inc. (CTRVP) has filed 6 10-Q, 22 8-K, 2 DEF 14A, 2 10-K, 1 8-K/A, 1 S-1/A, 2 10-K/A, 2 S-1, 2 DEFA14A, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of CTRVP's 38 recent filings, 8 were flagged as high-risk, 20 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$7,620,965 |
| Cash Position | $2,321,078 |
Key Executives
- Dr. D. R. Ramakrishna
- Dr. Michael J. Sofia
- John Brancaccio
- Jeffrey J. Fessler, Esq.
- Seth A. Lemings, Esq.
- Dr. Gregory J. Glenn
- Dr. Michael J. Yost
- John Cavan
- Dr. D. Ashworth
- Dr. S. K. Sharma
- Mr. J. M. G. M. Van Der Velden
Industry Context
Hepion Pharmaceuticals operates in the highly competitive biopharmaceutical and diagnostics sectors. The company is navigating a landscape characterized by lengthy and expensive drug development cycles, stringent regulatory hurdles, and the increasing importance of diagnostic tools to guide therapeutic decisions. Recent strategic shifts suggest a move towards diversifying its portfolio into diagnostic areas, potentially seeking to leverage existing expertise or capitalize on emerging market needs.
Top Tags
pharmaceuticals (10) · corporate-governance (8) · delisting (6) · listing-standards (5) · 10-Q (4) · financials (4) · regulatory (4) · proxy-statement (4) · material-agreement (3) · equity-sale (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for nine months ended Sep 30, 2025 | $7,620,965 | Improved from $11,644,966 in 2024 |
| Research and development expenses for nine months ended Sep 30, 2025 | $445,512 | Decreased from $12,438,956 in 2024 |
| Cash as of September 30, 2025 | $2,321,078 | Increased from $406,408 at December 31, 2024 |
| Proceeds from common stock and warrant issuances | $9,000,000 | Key driver of cash increase |
| Asset impairment loss | $402,746 | Related to new diagnostic assets |
| Cash paid for New Day Diagnostics license | $525,000 | Part of the in-licensing deal |
| Common stock issued for New Day Diagnostics license | $270,629 | Part of the in-licensing deal |
| Maximum contingent value rights from Rencofilstat sale | $4,500,000 | Potential future payments from Panetta Partners Limited |
| Accumulated deficit as of September 30, 2025 | $245,440,771 | Indicates significant historical losses |
| Common shares outstanding as of November 12, 2025 | 11,620,317 | Increased from 139,168 at December 31, 2024 |
| Net Loss | $7.15M | Increased from $6.78M in prior year period for six months ended June 30, 2025. |
| Asset Impairment Loss | $402.7K | Recognized on new diagnostic license agreement with New Day Diagnostics LLC. |
| Cash | $2.92M | Increased from $406K at December 31, 2024, due to financing activities. |
| Proceeds from Equity Issuance | $9.0M | Key driver for increased cash balance during the six months ended June 30, 2025. |
| R&D Expenses | $445.5K | Significantly decreased from $9.68M in prior year due to wind-down of ASCEND-NASH trial. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Hepion Pharmaceuticals, Inc. (CTRVP)?
Hepion Pharmaceuticals, Inc. has 42 recent SEC filings from Jan 2024 to Nov 2025, including 22 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CTRVP filings?
Across 42 filings, the sentiment breakdown is: 8 bearish, 34 neutral. The dominant sentiment is neutral.
Where can I find Hepion Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Hepion Pharmaceuticals, Inc. (CTRVP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Hepion Pharmaceuticals, Inc.?
Key financial highlights from Hepion Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CTRVP?
The investment thesis for CTRVP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Hepion Pharmaceuticals, Inc.?
Key executives identified across Hepion Pharmaceuticals, Inc.'s filings include Dr. D. R. Ramakrishna, Dr. Michael J. Sofia, John Brancaccio, Jeffrey J. Fessler, Esq., Seth A. Lemings, Esq. and 6 others.
What are the main risk factors for Hepion Pharmaceuticals, Inc. stock?
Of CTRVP's 38 assessed filings, 8 were flagged high-risk, 20 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Hepion Pharmaceuticals, Inc.?
Forward guidance and predictions for Hepion Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.